Hematology

TIL Therapy to be Assessed in Relapsed/Refractory Melanoma

October 9th 2022

ALLO-501A received RMAT designation from the FDA in June 2022.

$TIL Therapy to be Assessed in Relapsed/Refractory Melanoma$

CGTLive’s Weekly Rewind – October 7, 2022

October 7th 2022

Lyell will soon initiate a phase 1 trial of LYL845 with initial data expected in 2024.

Samir Parekh, MD, on Investigating Treatment Options for Relapsed Myeloma

October 7th 2022

Review top news and interview highlights from the week ending October 7, 2022.

Samir Parekh, MD

October 7th 2022

The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.

New, Multicenter Trial of MB-106 Doses First Patient

Around the Helix: Cell and Gene Therapy Company Updates – October 5, 2022

October 6th 2022

Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.

B-NHL Cell Therapy Cleared for Trials

October 5th 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion Chemotherapy

October 5th 2022

Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.

Sid Kerkar, MD

October 4th 2022

The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.

Advancing Neonatal Cell Therapy Research

Atul Malhotra, MD, PhD

October 3rd 2022

Newborn Cell Therapies Group at Monash University has received a $50,000 grant from Lions Cord Blood foundation.

Allogeneic Anti-CD7 CAR-T Demonstrates Promising Results in Hematological Malignancies

Omidubicel Improves Survival in Hematologic Malignancies With HSCT

October 2nd 2022

Among the 11 patients evaluated for efficacy, 9 patients (81.8%) had objective responses at 28 days.

BioMarin Resubmits BLA for Hemophilia A Gene Therapy Val-Rox

October 1st 2022

Disease-free survival was 56% in 105 participants over 3 years.

CGTLive’s Weekly Rewind – September 30, 2022

A prior resubmission in June 2022 was delayed with requests for additional durability and safety data.

Modified Immune Cell Therapy Induces Kidney-Donor-Specific Immunosuppression

Review top news and interview highlights from the week ending September 30, 2022.

GPRC5D-Targeted CAR-T Shows Promise in Heavily Pre-treated Multiple Myeloma

Patients treated with the highest dose of MIC-Lx had lymphocyte reactivity against third-party cells but not stimulatory donor blood cells.

Working With the Community to Improve Patient Access to Trials, Therapies

Of the 17 patients treated, 12 patients achieved a response, including 6 who achieved a complete response.

Rob Richards

Allogeneic CAR T Recognized for Cutaneous T-Cell Lymphomas

Rob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.

Around the Helix: Cell and Gene Therapy Company Updates – September 28, 2022

September 29th 2022

CTX-130 is being investigated in phase 1 studies for relapsed/refractory T or B-cell malignancies and renal cell carcinoma.

Leaping the Next Hurdle in CAR T-Cell Therapies

September 28th 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Phil Cyr

September 28th 2022

Phil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.

Vertex Continues Gene Therapy Momentum in Blood Disorders With Exa-Cel Submission

Jeffrey Miller, MD, on Emerging Research With Natural Killer Cells

September 27th 2022

Bluebird bio’s ZYNTEGLO was the first gene therapy to be approved in the space in August 2022.

Jeffrey Miller, MD

September 24th 2022

The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.

CGTLive’s Weekly Rewind – September 23, 2022

Pfizer, Sangamo Reopen Phase 3 Study of Hemophilia A Gene Therapy

September 23rd 2022

Review top news and interview highlights from the week ending September 23, 2022.

Switchable CAR-T Shows Promise in B-Cell Malignancies

September 23rd 2022

The FDA previously lifted its clinical hold of the AFFINE study in May 2022.

Zevor-Cel Yields 100% ORR in R/R Multiple Myeloma

September 22nd 2022

Interim data showed a 78% overall response rate and a 67% complete response rate.

Around the Helix: Cell and Gene Therapy Company Updates – September 21, 2022

September 22nd 2022

Eleven patients in the LUMMICAR-2 trial were evaluable for preliminary efficacy analyses.

Post-transplant AML Cell Therapy Receives $2 Million FDA Grant

September 21st 2022

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Cilta-Cel Yields High MRD-Negativity Rates in Multiple Myeloma After Prior Anti-BCMA Treatment

September 21st 2022

The grant will specifically help support the trial’s treatment arm for patients with post-transplant acute myeloid leukemia with minimal residual disease.

Chris Ryan

September 20th 2022

Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.

CGTLive’s Weekly Rewind – September 16, 2022